In fact, CBI is thought to act by blocking this tumor-induced T lymphocyte suppression, thus allowing CD8+ T lymphocytes to recognize HLA class I molecule – neoantigen complexes and kill the tumor cell. The gene discussed is CD8A; the disease is neoplasm.